AC-0676

N/A

Report date: 2023/03/28 14:01:16
NME

Base Information

Drug NameAC-0676
Drug Alias NameAC-0676AC0676AC-676AC676
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAutoimmune DiseasesHematologic NeoplasmsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAccutar Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesAccutar Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsAutoimmune DiseasesHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A